JP2011523052A - Ｇｌｐ−１受容体アゴニスト・バイオアッセイ - Google Patents

Ｇｌｐ−１受容体アゴニスト・バイオアッセイ Download PDF

Info

Publication number
JP2011523052A
JP2011523052A JP2011510592A JP2011510592A JP2011523052A JP 2011523052 A JP2011523052 A JP 2011523052A JP 2011510592 A JP2011510592 A JP 2011510592A JP 2011510592 A JP2011510592 A JP 2011510592A JP 2011523052 A JP2011523052 A JP 2011523052A
Authority
JP
Japan
Prior art keywords
glp
camp
sample
receptor agonist
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011510592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523052A5 (enExample
Inventor
ミチャリス・ニコラオウ
フレデリック・チャールズ・バンクロフト
ジョン・パトリック・ヘリッチ
アウン・ナイン・ルウィン
スワティ・グプタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of JP2011523052A publication Critical patent/JP2011523052A/ja
Publication of JP2011523052A5 publication Critical patent/JP2011523052A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
JP2011510592A 2008-05-23 2009-05-15 Ｇｌｐ−１受容体アゴニスト・バイオアッセイ Pending JP2011523052A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5584208P 2008-05-23 2008-05-23
US61/055,842 2008-05-23
PCT/US2009/044135 WO2009143014A1 (en) 2008-05-23 2009-05-15 Glp-1 receptor agonist bioassays

Publications (2)

Publication Number Publication Date
JP2011523052A true JP2011523052A (ja) 2011-08-04
JP2011523052A5 JP2011523052A5 (enExample) 2012-06-28

Family

ID=41202523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510592A Pending JP2011523052A (ja) 2008-05-23 2009-05-15 Ｇｌｐ−１受容体アゴニスト・バイオアッセイ

Country Status (4)

Country Link
US (2) US8329419B2 (enExample)
EP (1) EP2288918A1 (enExample)
JP (1) JP2011523052A (enExample)
WO (1) WO2009143014A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US20120048003A1 (en) * 2010-08-24 2012-03-01 GOLDEN PRODUCTS LLC, Limited Liability Company Vitamin assay methods
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
WO2012037361A2 (en) * 2010-09-15 2012-03-22 Endacea, Inc. Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN103424496B (zh) * 2012-05-24 2015-02-18 山东绿叶制药有限公司 一种测定痕量艾塞那肽的方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
CN103344764B (zh) * 2013-06-19 2014-11-26 天津美德太平洋科技有限公司 胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104569419B (zh) * 2014-09-23 2016-07-06 范列英 一种检测人血液glp-1总含量的化学发光免疫分析法试剂盒
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR102706686B1 (ko) 2016-05-06 2024-09-19 아이오니스 파마수티컬즈, 인코포레이티드 Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
JP7712210B2 (ja) 2019-04-01 2025-07-23 ノヴォ ノルディスク アー／エス リラグルチドに対する抗体およびその使用
EP4259646A1 (en) * 2020-12-11 2023-10-18 IP2IPO Innovations Limited Novel compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005527A2 (en) * 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672128B1 (fr) * 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
FR2810406B1 (fr) 2000-06-15 2002-09-20 Cis Bio Int Nouveaux cryptates de terre rare peu sensibles a l'extinction de fluorescence
WO2006005469A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
US20060275288A1 (en) * 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005527A2 (en) * 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013025518; ＴＥＣＡＮ　アプリケーションノート , 2007 *

Also Published As

Publication number Publication date
US20110097751A1 (en) 2011-04-28
WO2009143014A1 (en) 2009-11-26
US8603761B2 (en) 2013-12-10
EP2288918A1 (en) 2011-03-02
US20130089878A1 (en) 2013-04-11
US8329419B2 (en) 2012-12-11

Similar Documents

Publication Publication Date Title
US8329419B2 (en) GLP-1 receptor agonist bioassays
Varndell et al. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry.
JP7610535B2 (ja) セリアック病の診断、スクリーニング、および治療のための患者由来腸オルガノイドの使用
JP5281594B2 (ja) グルカゴン様ペプチド−２、ならびにその治療への使用
Bhat et al. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties
Hartmann et al. Structure, measurement, and secretion of human glucagon-like peptide-2
US7888317B2 (en) Glucagon-like peptide-2 and its therapeutic use
Windeløv et al. Why is it so difficult to measure glucagon-like peptide-1 in a mouse?
EP0906338B1 (en) Glucagon-like peptide-2 analogs
US5789379A (en) Glucagon-like peptide-2 analogs
US7781401B2 (en) Glucagon-like peptide-2 analogs
EP0914341B1 (en) Antagonists of intestinotrophic glp-2 peptides
JP2011523052A5 (enExample)
TW200922615A (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
Sebokova et al. Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency
Pederson et al. Discovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflections
CN107201342A (zh) 一种用于筛选肽类和非肽类glp‑1类似物的细胞株及其制备方法与应用
Kim et al. Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7–37)/polymer conjugate to isolated rat islets
WO2024133236A2 (en) Peptide conjugates for labelling endogenous gipr and glp-1r
Janabi Proinsulin C-peptide-mediated signalling and the search for its receptor
Lafferty et al. PYY (1-36) peptides from phylogenetically ancient fish targeting mammalian NPY1 receptors demonstrate potent effects on pancreatic beta-cell function, growth and survival
Van Noorden et al. Regulatory peptide immunocytochemistry at light-and electron microscopical levels
HK1153482A (en) Glucagon-like peptide-2 derivatives and their therapeutic use
HK1149720A (en) Glucagon-like peptide-2 and its therapeutic use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101122

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130228

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130826

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130902

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140225